Johnson & Johnson offers up to $5.5bn to settle US baby powder lawsuits
The healthcare giant proposes a multi-billion dollar payout to close a prolonged legal battle over its talc-based baby powder products.
Stock photo for illustration only, not from the actual event
- Johnson & Johnson proposes up to $5.5bn to settle US baby powder lawsuits
- The company plans to pay up to $3bn next year with no extra payments before 2028
- The deal requires approval from legal firms representing 95% of ovarian cancer claims
- J&J has consistently denied that its talc products caused cancer or asbestos contamination
New Jersey-based healthcare giant Johnson & Johnson has put forward a landmark settlement proposal worth up to $5.5 billion to resolve a long-standing legal dispute that has burdened the company for years. The lawsuits stem from consumers and surviving family members alleging that J&J's talc-based baby powder caused cancer due to contamination with asbestos, a hazardous natural mineral often found in proximity to talc deposits in the earth.
Despite introducing the multi-billion dollar payout, J&J continues to deny that its talc products caused cancer. The corporation has already altered the formula of its baby powder and halted global sales of the talc-based version in 2022, more than two years after pulling it from the US market. Furthermore, consumer healthcare company Kenvue—housing famous brands like Band-Aid, Listerine, and Calpol—was successfully spun off from J&J in 2022.
Under the proposed terms, J&J announced it will offer up to $3 billion next year, with zero additional payments scheduled before 2028. However, the agreement cannot be finalized until it receives formal acceptance from law firms representing 95% of the ovarian cancer claims active in both state and federal courts.
Stock photo for illustration only, not from the actual event
The talc litigation saga represents one of the most significant product liability challenges in modern corporate history, highlighting how raw material sourcing and contamination risks can severely impact global healthcare brands. Although a federal court earlier in July handed J&J a victory by challenging plaintiffs' ability to directly link talc to ovarian cancer, pursuing massive financial settlements remains a common strategic maneuver to eliminate long-term courtroom uncertainties and brand overhang.
"the company is confident that it would have 'ultimately prevailed with further litigation' just as it has in the majority of cases heard in court to date."
Haas
Source: BBC Business
Found something wrong in this article? Report an issue with this article
Comments
Leave a Comment